肝硬化伴难治性腹水患者托伐普坦的血浆浓度和疗效。

Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites.

机构信息

Department of Gastroenterology, Juntendo University Nerima Hospital, Tokyo, Japan.

出版信息

J Pharmacol Sci. 2019 Apr;139(4):373-376. doi: 10.1016/j.jphs.2019.01.015. Epub 2019 Feb 27.

DOI:10.1016/j.jphs.2019.01.015

Abstract

To investigate the relationship between the exposure and efficacy of tolvaptan, we measured pharmacokinetics of total drug at 7 days after repeated doses of 3.75 mg/day tolvaptan in 16 patients with hepatic edema. Nine patients (56.3%) were responders, which were defined as those with body weight reduction of >1.5 kg/week. Serum albumin levels were significantly lower in responders than in non-responders (P = 0.031). However, the pharmacokinetics varied greatly among individuals and was not relevant to the clinical response.

摘要

为了研究托伐普坦的暴露量与疗效之间的关系，我们在 16 例肝性水肿患者中测量了重复给予托伐普坦 3.75mg/天 7 天后的总药物药代动力学。9 例患者（56.3%）为应答者，即每周体重减轻＞1.5kg 的患者。应答者的血清白蛋白水平明显低于无应答者（P=0.031）。然而，药代动力学在个体之间差异很大，与临床反应无关。